Cargando…

FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy

Our aim was to analyse whether biomarkers extracted from baseline (18)F-FDG PET before anti-PD1 treatment contribute to prognostic survival information for early risk stratification in metastatic melanoma. Fifty-six patients, without prior systemic treatment, BRAF wild type, explored using (18)F-FDG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flaus, A., Habouzit, V., De Leiris, N., Vuillez, J. P., Leccia, M. T., Perrot, J. L., Prevot, N., Cachin, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458464/ https://www.ncbi.nlm.nih.gov/pubmed/34552135 http://dx.doi.org/10.1038/s41598-021-98310-3

Ejemplares similares

Outcome Prediction at Patient Level Derived from Pre-Treatment 18F-FDG PET Due to Machine Learning in Metastatic Melanoma Treated with Anti-PD1 Treatment
por: Flaus, Anthime, et al.
Publicado: (2022)

Decision Tree With Only Two Musculoskeletal Sites to Diagnose Polymyalgia Rheumatica Using [(18)F]FDG PET-CT
por: Flaus, Anthime, et al.
Publicado: (2021)

Quantitative Dynamic (18)F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Interim [(18)F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
por: Sachpekidis, Christos, et al.
Publicado: (2020)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [(18)F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
por: Lopci, Egesta
Publicado: (2021)

Can physiologic colonic [(18)F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
por: Sachpekidis, Christos, et al.
Publicado: (2023)

[(18)F]FDG PET/CT in the Evaluation of Melanoma Patients Treated with Immunotherapy
por: Mangas Losada, María, et al.
Publicado: (2023)

Advantages of FBPA PET in evaluating early response of anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice: Comparison to FDG PET
por: Tatsumi, Mitsuaki, et al.
Publicado: (2022)

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma
por: Youland, Ryan S., et al.
Publicado: (2017)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

Brain Metastases Unresponsive to Immunotherapy Detected by 18F-FDG-PET/CT in a Patient with Melanoma
por: Fonti, Rosa, et al.
Publicado: (2020)

The prognostic value of [(18)F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria
por: Sachpekidis, Christos, et al.
Publicado: (2023)

FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
por: Mignard, Claire, et al.
Publicado: (2018)

Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
por: Ferdinandus, Justin, et al.
Publicado: (2022)

Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative (18)F-FDG PET/CT analysis
por: de Heer, Ellen C., et al.
Publicado: (2018)

Assessment of early metabolic progression in melanoma patients under immunotherapy: an (18)F-FDG PET/CT study
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
por: Dupuis, Frantz, et al.
Publicado: (2018)

FDG-PET/CT for lymph node staging prior to radical cystectomy
por: Pihl, Vilhelm, et al.
Publicado: (2023)

Comparing the associations between host and tumor factors with survival outcomes with anti‐PD‐1 immunotherapy in metastatic melanoma
por: Koczka, Kim, et al.
Publicado: (2022)

PET image enhancement using artificial intelligence for better characterization of epilepsy lesions
por: Flaus, Anthime, et al.
Publicado: (2022)

The Role and Potential of (18)F-FDG PET/CT in Malignant Melanoma: Prognostication, Monitoring Response to Targeted and Immunotherapy, and Radiomics
por: Filippi, Luca, et al.
Publicado: (2022)

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
por: Goldfarb, Lucas, et al.
Publicado: (2019)

(18)F-FDG PET-CT for Staging of Conjunctival Melanoma
por: Damian, Andres, et al.
Publicado: (2013)

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
por: Vera Aguilera, Jesus, et al.
Publicado: (2020)

Beyond PD-1 Immunotherapy in Malignant Melanoma
por: Kwiatkowska, Dominika, et al.
Publicado: (2019)

(18)F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
por: Wong, Annie, et al.
Publicado: (2020)

Improving therapy in metastatic uveal melanoma by understanding prior failures
por: Olson, Daniel J., et al.
Publicado: (2020)

Predictive value and accuracy of [(18)F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma
por: Ayati, Narjess, et al.
Publicado: (2023)

FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate
por: Liu, Yiyan
Publicado: (2008)

FDG-PET/CT findings of a metastatic pituitary tumor
por: Ilkhchoui, Yashar, et al.
Publicado: (2010)

Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
por: Thatcher, N., et al.
Publicado: (1977)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy
por: Amato, Carol M., et al.
Publicado: (2020)

Candida Esophagitis Incidentally Detected by 18F-FDG PET/CT in Metastatic Lung Adenocarcinoma
por: Martínez-Amador, N, et al.
Publicado: (2017)

Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT
por: Pattison, David A., et al.
Publicado: (2019)

Colonic Malignant Melanoma: (18)F-FDG PET/CT Findings
por: Kaya, Eser, et al.
Publicado: (2018)

Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients
por: Schiza, Aglaia, et al.
Publicado: (2019)

In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
por: Babačić, Haris, et al.
Publicado: (2020)

Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ujskofmor3sefegd2037sm2pga